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The Synthesis and Biological Activity of Iron Binding Motifs 
An Honors Thesis submitted in partial fulfillment of the requirements for Honors in 
Chemistry. 
 
By  Rachel Burke 
Under the mentorship of Dr. Michele McGibony 
Abstract 
Iron is an essential mineral that plays a key role in the oxygen transporting 
molecule hemoglobin.  Iron also helps muscles store and use oxygen.  Excess iron in the 
body can attract electrons, creating harmful oxygen radicals.  Iron overload can be caused 
by several factors such as genetics, age, gender, and having received multiple red blood 
cell transfusions. Excess iron can lead to many diseases, such as arthritis, liver cirrhosis, 
heart disease, and several forms of cancer.  Iron-chelating therapies work by binding free 
iron in the bloodstream and by reducing the amount of iron bound in transferrin, the iron 
transporting molecule.  Current iron therapies are time-consuming, painful, and costly.  
New, more effective chelation therapies are being researched. 
 The first step in this research is to synthetically produce iron binding motifs 
modeled after the naturally occurring iron binding protein, adenochrome.  The goals in 
the synthesis are to produce a chelator with increased water solubility and a higher 
affinity for chelation of iron.  The next step is to test the effectiveness of the synthesized 
chelators to bind free iron, as well as other first row transition elements, such as 
chromium, copper, nickel, and aluminum.  Evidence has shown that accumulation of 
aluminum in the body may be involved in the formation of senile plaques, which occur in 
the brains of patients with Alzheimer’s disease, and is therefore a suspect in the initial 
cause of the disease.  The binding of aluminum could be beneficial in the therapy of early 
Alzheimer’s patients.  
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Introduction 
 Iron is an essential metal ion for animals, plants, and bacteria, and it is one of the 
most common metals in the environment.  While iron is important in many metabolic 
processes in the body, the most commonly known is the role of iron in the transport of O2 
and other molecules in the bloodstream.  The heme group embedded in myoglobin and 
the subunits of hemoglobin binds these molecules for transport in the bloodstream.  
Additionally, iron is involved in many other biological processes such as the transfer of 
electrons in cytochrome P-450, cytochrome proteins in the electron transport chain, and 
methane monooxygenase, an oxidoreductase enzyme found in methanotrophic bacteria. 
Iron can serve a wide variety of purposes mainly because it is so versatile.  This is 
due to the fact that iron is stable at two different oxidation states, Ferric iron at 3+, and 
Ferrous iron at 2+.  Iron possesses unfilled d orbitals, allowing it to undergo Fenton 
chemistry, reactions involving the change in oxidation states1.  These reactions will 
generate several reactive species including the superoxide radical, the hydroxyl radical, 
and the hydroperoxyl radical as demonstrated in the reactions below.  While iron is very 
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important in many metabolic processes, too much can do more harm than good when 
these reactive species are in high concentrations. 
Reaction #1:  Fe2+ + H2O2 → Fe3+ + HO• + OH– 
Reaction #2 Fe3+ + H2O2 → Fe2+ + HOO• + H+ 
In the United States, diseases arising from the body’s mismanagement of iron 
levels in the blood stream affect over 3 million people. Some examples of these health 
conditions include rheumatoid arthritis, certain cancers, and, the target of this research, 
hemochromatosis.  Hemochromatosis is the most common genetic disease in the U.S.A. 
according to the U.S. Centers for Disease Control and Prevention (CDC) in Atlanta, 
Georgia.  Patients with hemochromatosis may experience arthritis-like pain, cirrhosis or 
cancer of the liver, diabetes, chronic fatigue, infertility, and sometimes stroke.  
Approximately 1.5 million Americans are carriers of the double gene responsible for 
fully developed hemochromatosis5.  Iron overload as a condition can accelerate 
neurodegenerative diseases, such as Alzheimer’, early-onset Parkinson’s, Huntington’s 
disease, epilepsy, and multiple sclerosis1. 
The treatment options for hemochromatosis are limited and include phlebotomy 
and iron chelation therapies.  Phlebotomy is the regular removal of blood, and can only 
be done if patients’ hemoglobin levels are sufficient.  Currently, the only viable drug for 
iron chelation is Desferrioxamine B (DFO, Desferal®)(Figure 1).  This drug works by 
chelating (binding) iron and enhancing its elimination by the body via the urine.  This 
molecule is naturally occurring as it is a bacterial siderophore produced by the 
Actinobacteria  Streptomyces pilosus and contains one of the most stable ferric iron 
binding motifs ever identified.      
 Figure 1:  Desferrioxamine B
While this drug works well for iron chelation, the
painful, because treatment is administered intravenously, in a
Recent research in the area of oral iron
chelation agents which contain hydroxamate and/or catechol ligands
myxochelines, which mimic natural siderophores
such hydroxamate ligane molecule (Figure 3). 
chelators but none that have better binding affinity than Desferal
Figure 2:  Myxochelines, a c
ligand molecule
The most recent work has focused 
and O-TRENSOX (Figure 4.)
and ferrous iron) and water solubility studies, but, they only work in systems with very 
low pH.  With its current design, TRENSOX would be completely ineffective in a system 
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Figure 3:  Desferrioximane E, a 
hydroxamate ligand molecule
on the TRENSOX drugs.  Both N
 have shown promising results in iron binding 
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with physiological pH.  O-Trensox has been shown in vitro to remove iron from ferritin 
at pH of 4 and mobilize hepatic iron in rats in similar amounts to Desferal.  O-Trensox 
was found to be more effective the Desferal in quenching hydroxyl radical in an acellular 
system6. 
 
Figure 4. The structure of O-TRENSOX and N-Trensox7. 
  The goal of this research is to create new binding motifs that will be stable, water 
soluble, and effective at biological pH.  To accomplish these tasks, the quinoline units 
(Figure 5) of TRENSOX amines were replaced with electron-rich indole units (Figure 6) 
in order to reduce total carbon amount and increase solubility.   
 Figure 5. Structure of Quinoline
The proposed synthetic mimics are 
Acid.  
 
                         Figure 7:  Tris
 
Both compounds present in a claw shape (Figure 9) very similar to N and O
Trensox. This tripodal shape puts the oxygens in the optimal p
coordination.  The proposed synthetic biomimics will first be synthesized in our 
collaborator Dr. Christine Whitlock's laboratory, then thermodynamic and kinetic studies 
which will determine the binding strength and stability of the metal
iron and other relevant first
 
8
. Figure 6. Structure of Indole
Tris-Indole and Tris-Indole 3-
 
 
-Indole                    Figure 8: Tris-Indole 3-
osition for iron 
-protein complex with 
-row transition elements such as aluminum, cobalt, copper.  
Burke  5 
 
9
. 
Carboxylic 
Carboxylic Acid             
-
Burke  
 
6 
The studies will determine the possibility of iron binding motifs among first row 
transition metals by comparing complexed iron. After synthesis, NMR and Mass 
spectrometry will be utilized to confirm the identity of the proposed drugs. 
 
 
Figure 9. Claw shape of tripodal compound. 
 
Materials and Methods 
Synthesis of Iron Binding Compounds 
To prepare the first derivative, Tris(2-[indole-3-glyoxylamido]ethyl)amine. To 
indole (10.07 g, 86.1 mmol) in ether (200 mL) was added dropwise oxalyl choride (14.6 
g, 114.6 mmol) over 15 mins. After stirring for 30 min, the solution was filtered to yield 
glyoxalyl chloride as a yellow solid, which was rapidly dissolved in Tetrahydrofuran 
(THF) (50 mL). To the glyoxalyl in THF at 0°C was added a solution of tris(2-
aminoethyl)amine (TREN) (6.14 g, 42.0 mmol) and triethylamine (42.3 mmol) in THF 
(10 mL). After stirring at 0°C for 1 hour, the solution was filtered and the filtrate was 
evaporated to yield the Tris-Indole as a beige solid which crystallized from MeOH 
Burke  
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(Scheme 1). Yield 5.93 g (31.4%); mp > 250°C. 1 H-NMR (250 MHz, DMSO-d6) 8.75 
(s, 3H, H2), 8.65 (t, J=5.29 Hz, 3H, H1), 8.14 (d, J=6.9 Hz, 3H, H4), 7.47 (d, J=7.1 Hz, 
3H, H7), 7.22 (t, J=7.0 Hz, 3H, H5 or H6), 7.16 (t, J=7.0 Hz, 3H, H6 or H5), 3.31 (m, 6H, 
Ha), 2.71 (bt, 6H, Hb); MS (M+1)+  = 660 for C36H33N7O610. 
 
Scheme 1:  Schematic of synthesis of Tris-Indole. 
Having established success in the preparation of the first derivative, a related 
tripodal amine with one carbonyl unit per arm was also prepared by a modification of the 
previously stated procedure, Tris(2-[indole-3-amido]ethyl)amine. Indole-3-carboxylic 
acid (0.56 g, 3.4 mmol) dissolved in SOCl2 (6 mL) was stirred at 0°C. After 1.5 hours, 
the solution was rotary evaporated, and to the resulting oil was added TREN (0.62 g, 4.2 
mmol) and triethanolamine (0.46 g, 4.6 mmol) in THF (25 mL). After stirring at 0°C for 
30 min, the solution was vacuum filtered to yield the Tris-Indole-3-Carboxylic Acid as a 
beige solid which was recrystallized from MeOH (Scheme 2). Yield 0.28 g (43.0%); mp 
> 250°C. 1 H-NMR (250 MHz, DMSO-d6) 7.98 (s, 3H, H2), 7.44 (m, 3H, H1), 7.17 (m, 
3H, H4), 7.15 (d, 3H, H7), 7.14 (m, 3H, H5 or H6), 7.12 (m, 3H, H6 or H5), 3.40 (m, 
12H, Ha and Hb); MS (M+1)+ = 576 for C33H33N7O310. 
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Scheme 2:  Schematic of synthesis of Tris-Indole-3-Carboxylic Acid. 
 
Biological Activity in Solution 
Tris-Indole or Tris-Indole 3-Carboxylic acid was added to stock iron nitrate 
solution (50 mg/mL) Fe(NO3)3 in a 1:1 and 1:2 ratio. Similarly, the synthetic mimics 
were combined with stock metal chloride solutions (100 mg/mL) each of cobalt chloride 
and chromium chloride.  Each sample was incubated for 2 hours and analyzed every 30 
minutes via UV-Visible spectrophotometry (UV-1601 Shimadzu).  
  
Biological Activity with partially loaded Human Transferrin 
Tris-Indole or Tris-Indole 3-Carboxylic acid was added to human transferrin 
(partially loaded from Sigma).  The synthetic compounds were also added to transferrin 
and stock (50 mg/mL) Fe(NO3)3 in a 1:1 and 1:2 ratio.  Each sample was incubated for 2 
hours and analyzed every 30 minutes via UV-Visible spectrophotometry (UV-1601 
Shimadzu).  Each sample was chromatographed (bed volume ~15 mL) using Sephadex 
G-10, and fractions were analyzed for both the drug and iron.  The iron-containing 
fractions were pooled and concentrated via lyophilization.  During this process the 
samples were dissolved in dH2O in order to ensure removal all of salt ions. 
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Miscellaneous 
H-NMR spectra were obtained using a Bruker 250 MHz multi- nuclear 
spectrometer. MS were measured using a Shimadzu QP 5050A instrument.   Melting 
points are uncorrected.  All concentrated samples were analyzed via UV-Visible 
spectroscopy (UV-1601 Shimadzu) and MALDI-ToF (Brucker Microflex) in order to 
determine extent of iron binding.  For all experiments either Trizma/Tris ( 50 mM, pH = 
7.42) or citrate ( 50 mM, pH = 7.47) buffers were utilized.  Synthetic compounds were 
dissolved in a minimum of DMSO.   
 
Results and Discussion 
Table 1. Percent yields of the synthetic mimics. 
Synthetic Mimic Yield 
Tris-Indole 31.4% 
Tris-Indole-3-Carboxylic Acid 43.0% 
 
 
 Graph 1. Tris-Indole with Iron at 475 nm
 
Graph 2. Tris-Indole 3-Carboxylic Acid with Iron at 475 nm
  
From the two graphs, see that Tris
Indole was incubated with Fe(NO
maximum indicated that within 1 hour iron was bound to this molecule as indicated in 
 
3
. 
 
3
. 
-Indole more successfully bound iron
3)3 and the absorbance at 475 nm increased reaching a 
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graph 1.  Increasing the ratio from 1:1 to 1:2 had no bearing on the time or amount of iron 
bound to the complex.  Tris-Indole-3-Carboxylic Acid was incubated with Fe(NO3)3 and 
the absorbance at 475 nm increased, reaching a maximum at 30 minutes for both a 1:1 
and 1:2 ratio.  Altering the ratio from 1:1 to 1:2 had no effect on the time or amount of 
iron bound to the complex. 
 
 
 
Graph 3. Elution profiles of both Tris-Indole and Tris-Indole Carboxylic Acid in iron 
solution3. 
 The middle peak in each of the elution profiles indicated the complexed iron.  The 
Tris Indole in both 1:1 and 1:2 ratios had visible peaks, indicating the presence of the 
complexed iron (Graphs A, C).  The Tris-Indole Carboxylic Acid with a 1:1 ratio (Graph 
B) has a minor peak, while the 1:2 ratio of the Tris-Indole Carboxylic Acid has little to no 
 peak.  The elution profiles indicate that the Tris
than did the Tris-Indole Carboxylic Acid.
Graph 4. Tris-Indole with Cobalt
 
Graph 5. Tris-Indole 3-Carboxylic Acid with Cobalt 
 
-Indole more successfully bound the iron 
 
 Chloride at 475 nm. 
Chloride at 475 nm.
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Graph 6. Tris-Indole with Chromium Chloride at 580 nm. 
 
 
Graph 7. Tris-Indole 3-Carboxylic Acid with Chromium Chloride at 580 nm. 
 
 The graphs of the absorbance at the specific wavelengths for Cobalt and 
Chromium show that the drugs had little to no binding of the free iron.  Over the 90 
minute period, none of the samples had more than a 0.05 absorbance at the corresponding 
wavelengths for the bound metal ions (Cobalt and Chromium). 
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Conclusion 
 The synthesis of Tris-Indole and Tris-Indole-3-Carboxylic Acid was successful, 
with yields of 31.4% and 43.0%, respectively.  There structures were confirmed via 
melting point, NMR, and MALDI-ToF.  From the absorbance graphs, it can be seen that 
that Tris-Indole derivative more successfully bound the free iron than did the Tris-Indole-
3-Carboxylic Acid. Maldi-Tof mass spec confirmed the total weight of the complex with 
the bound iron, indicating complexation of the complex with iron in the ferric oxidation 
state. While the absorbance graphs of the drugs with the cobalt and chromium no binding, 
alterations to the experimental procedure will be made in an attempt to increase binding.  
Future Work 
 Aluminum is ubiquitous in the environment. About ninety-five percent of 
aluminum is bound to transferrin and albumin intravascularly and is eliminated renally, 
but it can also exist as a free ion in the bloodstream, in small quantities13.  Aluminum is a 
widely recognized neurotoxin that inhibits more than 200 biologically important 
functions and causes various adverse effects in plants, animals, and humans, when it 
occurs in toxic levels.  Such effects include encephalopathy, osteomalacia, aplastic bone 
disease, proximal myopathy, increased risk of infection, and decreased myocardial 
function12.   
Like iron, aluminum is another metal ion associated with the acceleration of 
neurodegenerative diseases.  Studies have shown increased levels of aluminum in the 
brains of patients with Alzheimer’s disease.  One possible connection between aluminum 
and the progression of Alzheimer’s disease is the presence of concentrated aluminum in 
the extracellular senile plaques12.  It has been hypothesized and debated that elevated 
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levels of aluminum in brain tissue could be linked to the progression of Alzheimer’s 
disease. 
 Though aluminum is not a transition metal, we postulated that it may fall under 
the same binding motif as iron.  Due to the fact that aluminum is not a transition metal, 
the binding cannot be observed using the same methods as the other compounds tested.  
Atomic absorption spectrometry will be used to determine the binding ability of the 
synthetic mimics toward aluminum.   
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